Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Gemcitabine + Nab-Paclitaxel vs Gemcitabine in Fragile Pancreatic Cancer
NCT05841420Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in pancreatic cancer (PC) (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2023; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05841420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841420.